DLBCL: Real-World Use of Frontline Polatuzumab Vedotin Following the POLARIX Trial

The FDA granted fast track designation to NX-5948 for treating relapsed/refractory Waldenström macroglobulinemia after 2 or more lines of therapy, including a BTK inhibitor.

Here are some of the highlights from this year's 2024 ASH Annual Meeting & Exposition.

Memorial Sloan Kettering Cancer Center physicians describe challenges in diagnosis, patient care, and the potential expansion of telehealth in this continuation of November's coverfeature.

Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.

Data presented at ASH 2024 showed that tafasitamab led to a progression-free survival of 11.3 months and an overall survival of 24.8 months in patients with relapsed/refractory DLBCL.

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, overall cardiac adverse events, and heart failure in patients with B-cell hematologic malignancies.